Madam Chair, perhaps I can start. Then I'll ask a colleague to talk about the contractual negotiations.
It is a fact that the researchers at the National Research Council are familiar with the technology underlying the AstraZeneca vaccine. In fact, the facility that is being built, the biologics manufacturing facility, would have the capability to make that type of vaccine. The important matter, of course, is the company with which you're going to strike a deal to pursue that. In this case, we announced earlier this week the MOU with Novavax, which is to pursue production at that facility and in line with our capabilities, which have been mentioned.
I'll ask my colleague if he'd like to provide further information in terms of the discussions that were undertaken with each of the vaccine manufacturers, including AstraZeneca, which I think Minister Anand did address. It was part of those conversations at the early stage.